Ralf Schmid

Ralf has more than 20 years experience in M&A, licensing, public and private market transactions in various leading positions in the field of finance and administration in Biotech and at several multinational companies including Sandoz. He joined F2G in July 2016 from Nabriva Therapeutics AG where he had served on the management board since the company’s spin-off from Sandoz in 2006. In his role as Chief Financial and Chief Operating Officer, Ralf was instrumental in taking the company public on NASDAQ in September 2015. He holds a Master's degree in finance and economics from Otto-Friedrich-Universität Bamberg, Germany.